)
Peter Fruhstorfer
CEO,
noselab
Dr. Peter Fruhstorfer is Chief Executive Officer (CEO) at Noselab, a German biotechnology company.
Noselab has developed a proprietary platform making biomarker signatures of central nervous system (CNS) diseases accessible through a previously untapped biological gateway: the brain-nose interface (BNI) and nasal fluid.
Before joining Noselab in 2024, Peter was the CEO and Chief Business Officer at Eppendorf SE, a German lab equipment manufacturer, based in Hamburg. Prior to Eppendorf, Peter held various General Management positions at Thermo Fisher Scientific and Carl Zeiss.
Dr. Fruhstorfer holds a PhD in natural sciences and also provides services as a leadership mentor and Non-Executive Board Member.
Sessions